Clinical Trials Logo

Clinical Trial Summary

Approximately 9 participants will be enrolled in the study in a single cohort. Participants will be randomized to 3 g IXT-m200 or placebo at 7:2. Each will receive their dose as a 30-min intravenous infusion, then remain at the study site overnight to complete Day 1 and Day 2 assessments (e.g., electrocardiogram (ECG), laboratory assessments, blood draws, and vital signs). Following discharge on Day 2, participants will return to the clinic for follow-up pharmacokinetic (PK) and safety assessments on Day 8, then every 1-3 weeks thereafter until Day 127.

Clinical Trial Description


Study Design

NCT number NCT05027451
Study type Interventional
Source InterveXion Therapeutics, LLC
Contact Chief Operating Officer
Phone 5015542377
Email [email protected]
Status Not yet recruiting
Phase Phase 1
Start date September 20, 2021
Completion date February 8, 2022